Drugs & Targets FDA approves two Opdivo-based regimens in unresectable advanced or metastatic ESCC June 03, 2022Vol.48 No.22
Drugs & Targets FDA approves Kymriah in relapsed or refractory follicular lymphoma June 03, 2022Vol.48 No.22
Drugs & Targets FDA grants priority review to Omblastys in pediatric CNS/leptomeningeal metastasis from neuroblastoma June 03, 2022Vol.48 No.22
Drugs & Targets FDA grants Fast Track designation to PDS0101 + Keytruda in recurrent or metastatic HPV16-positive HNC June 03, 2022Vol.48 No.22
Drugs & Targets OncoHealth, Blue Note Therapeutics partner to provide a digital therapeutic for cancer-related anxiety and depression June 03, 2022Vol.48 No.22
Drugs & Targets C2i Genomics, Karkinos Healthcare partner to bring AI-powered cancer R&D to India June 03, 2022Vol.48 No.22
Capitol Hill House Republicans seek information on “me-too” drugs developed in China May 27, 2022Vol.48 No.21By Alice Tracey
Capitol Hill Cancer groups ask for $4.1 billion increase for NIH, $850 million boost for NCI in FY23 May 27, 2022Vol.48 No.21By Alice Tracey
